(NASDAQ: BOLD) Boundless Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.65%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.42%.
Boundless Bio's earnings in 2026 is -$55,994,000.On average, 3 Wall Street analysts forecast BOLD's earnings for 2026 to be -$54,992,144, with the lowest BOLD earnings forecast at -$52,835,589, and the highest BOLD earnings forecast at -$56,609,560. On average, 3 Wall Street analysts forecast BOLD's earnings for 2027 to be -$21,309,456, with the lowest BOLD earnings forecast at -$20,473,791, and the highest BOLD earnings forecast at -$21,936,204.
In 2028, BOLD is forecast to generate -$25,090,166 in earnings, with the lowest earnings forecast at -$34,343,133 and the highest earnings forecast at -$14,860,009.